Home
TLSA
TLSA News

Latest Tiziana Life Sciences Ltd. (TLSA) News on September 18, 2025

Promising Penny Stocks To Consider In June 2025

Simply Wall St.

3 months ago

Promising Penny Stocks To Consider In June 2025

MT Newswires

3 months ago

Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

GlobeNewswire

3 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Tiziana Life Sciences to Present at the Bio International Convention

GlobeNewswire

3 months ago

Tiziana Life Sciences to Present at the Bio International Convention

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

GlobeNewswire

4 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

GlobeNewswire

4 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

GlobeNewswire

4 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

3 Promising Penny Stocks With Market Caps Over $40M

Simply Wall St.

4 months ago

3 Promising Penny Stocks With Market Caps Over $40M

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

GlobeNewswire

4 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

Insider Monkey

5 months ago

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS

Clinical Trials Arena

5 months ago

Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

GlobeNewswire

5 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

GlobeNewswire

6 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis

Clinical Trials Arena

6 months ago

Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

GlobeNewswire

6 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

GlobeNewswire

6 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires

6 months ago

Tiziana Life Sciences Regains Compliance With Nasdaq Listing Rule

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

GlobeNewswire

6 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

Simply Wall St.

6 months ago

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

MT Newswires

6 months ago

Sector Update: Health Care Stocks Lower Late Afternoon

MT Newswires

6 months ago

Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

GlobeNewswire

6 months ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025

Insider Monkey

7 months ago

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

GlobeNewswire

7 months ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

GlobeNewswire

7 months ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

MT Newswires

7 months ago

Tiziana Life Sciences Teams Up With Renaissance Lakewood on Nasal Drug Delivery

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

GlobeNewswire

7 months ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

GlobeNewswire

7 months ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

3 Promising US Penny Stocks With Market Caps Over $20M

Simply Wall St.

7 months ago

3 Promising US Penny Stocks With Market Caps Over $20M

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

GlobeNewswire

7 months ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

MT Newswires

8 months ago

Tiziana Life Sciences' Foralumab Demonstrates Motor Function Improvement in Preclinical Spinal Cord Injury Studies

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

GlobeNewswire

8 months ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

MT Newswires

8 months ago

Sector Update: Health Care Stocks Gain Thursday Afternoon

MT Newswires

8 months ago

Tiziana Life Sciences Says it Has No Immediate Capital Raising Plans; Shares Fall

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

GlobeNewswire

8 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

GlobeNewswire

8 months ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

3 Penny Stocks In US With Market Caps Below $300M

Simply Wall St.

8 months ago

3 Penny Stocks In US With Market Caps Below $300M

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

GlobeNewswire

8 months ago

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

GlobeNewswire

8 months ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

GlobeNewswire

9 months ago

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

3 US Penny Stocks With Market Caps Under $200M To Consider

Simply Wall St.

9 months ago

3 US Penny Stocks With Market Caps Under $200M To Consider

Tiziana Life Sciences expands Phase 2 trial for non-active SPMS

TipRanks

9 months ago

Tiziana Life Sciences expands Phase 2 trial for non-active SPMS

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

GlobeNewswire

9 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

Tiziana Life Sciences Secures ALS Trial Funding

TipRanks

10 months ago

Tiziana Life Sciences Secures ALS Trial Funding

MT Newswires

10 months ago

Tiziana Life Sciences Says Grant Application Approved by ALS Association

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

GlobeNewswire

10 months ago

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

GlobeNewswire

a year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

GlobeNewswire

a year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

GlobeNewswire

a year ago

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Discover October 2024's Promising US Penny Stocks

Simply Wall St.

a year ago

Discover October 2024's Promising US Penny Stocks

Tiziana Life Sciences Plans Share Sale with Jefferies

TipRanks

a year ago

Tiziana Life Sciences Plans Share Sale with Jefferies

Tiziana Life Sciences Advances with Promising Drug Trials

TipRanks

a year ago

Tiziana Life Sciences Advances with Promising Drug Trials

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

GlobeNewswire

a year ago

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

MT Newswires

a year ago

Tiziana Life Sciences Names Ivor Elrifi as CEO

Tiziana Life Sciences Appoints New Chief Executive Officer

GlobeNewswire

a year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

MT Newswires

a year ago

Tiziana Life Sciences Regains Nasdaq Minimum Bid Requirement

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

GlobeNewswire

a year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Granted FDA Fast Track Designation

GlobeNewswire

a year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

MT Newswires

a year ago

Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies

Tiziana Receives $3.4 Million in Non-Dilutive Funding

GlobeNewswire

a year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

GlobeNewswire

a year ago

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

MT Newswires

a year ago

Tiziana Says FDA Accepts Fast Track Label Submission For Multiple Sclerosis Treatment

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

GlobeNewswire

a year ago

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Investor's Business Daily

a year ago

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Business Wire

a year ago

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

Investor's Business Daily

a year ago

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

EnviroGold Global Closes First Tranche of Private Placement

GlobeNewswire

a year ago

EnviroGold Global Closes First Tranche of Private Placement

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

How markets digested hot jobs print: Top takeaways

Yahoo Finance Video

a year ago

How markets digested hot jobs print: Top takeaways

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

PR Newswire

a year ago

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

MT Newswires

a year ago

Tiziana Life Sciences' Foralumab Demonstrates Qualitative Improvement in Multiple Sclerosis Patients After 6 Months Use

Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab

GlobeNewswire

a year ago

Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab

Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab

GlobeNewswire

a year ago

Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

GlobeNewswire

a year ago

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

GlobeNewswire

a year ago

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

GlobeNewswire

a year ago

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

MT Newswires

a year ago

Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

GlobeNewswire

a year ago

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

GlobeNewswire

a year ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

GlobeNewswire

a year ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

GlobeNewswire

a year ago

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

GlobeNewswire

a year ago

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

GlobeNewswire

2 years ago

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

Gabelli Funds to Host Pump, Valve & Water Systems Symposium at The Yale Club, New York, NY

GlobeNewswire

2 years ago

Gabelli Funds to Host Pump, Valve & Water Systems Symposium at The Yale Club, New York, NY

Allspring Closed-End Funds Declare Monthly Distributions

PR Newswire

2 years ago

Allspring Closed-End Funds Declare Monthly Distributions

Strength Seen in Modiv Industrial, Inc. (MDV): Can Its 7.1% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in Modiv Industrial, Inc. (MDV): Can Its 7.1% Jump Turn into More Strength?

ESGEN Acquisition Corp. Announces Updated Transaction Terms for its Pending Business Combination with Sunergy Renewables

GlobeNewswire

2 years ago

ESGEN Acquisition Corp. Announces Updated Transaction Terms for its Pending Business Combination with Sunergy Renewables

D-Wave Joins Forces with Deloitte Canada to Advance Quantum Adoption

Business Wire

2 years ago

D-Wave Joins Forces with Deloitte Canada to Advance Quantum Adoption

Business Wire

2 years ago

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

SurgePays Announces Proposed Public Offering

GlobeNewswire

2 years ago

SurgePays Announces Proposed Public Offering

Velo3D to Present at the 26th Annual Needham Growth Conference

Business Wire

2 years ago

Velo3D to Present at the 26th Annual Needham Growth Conference

A Look At The Intrinsic Value Of FAT Brands Inc. (NASDAQ:FAT)

Simply Wall St.

2 years ago

A Look At The Intrinsic Value Of FAT Brands Inc. (NASDAQ:FAT)

TLSA: First Phase II SPMS Patient Dosed

Zacks Small Cap Research

2 years ago

TLSA: First Phase II SPMS Patient Dosed

Solid Biosciences Announces $109 Million Private Placement

GlobeNewswire

2 years ago

Solid Biosciences Announces $109 Million Private Placement

Business Wire

2 years ago

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

GlobeNewswire

2 years ago

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

GlobeNewswire

2 years ago

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

GlobeNewswire

2 years ago

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Share on Social Networks: